康緣藥業(600557.SH):公司部分藥品納入《國家醫保目錄》
格隆匯11月29日丨康緣藥業(600557.SH)公佈,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2024年)>的通知》。根據該通知,江蘇康緣藥業股份有限公司獨家品種濟川煎顆粒首次通過談判納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2024年)》。公司品種筋骨止痛凝膠(獨家品種)、苓桂術甘顆粒本次從談判目錄調整至國家醫保常規目錄;吡侖帕奈片、泊沙康唑腸溶片是公司2023年、2024年新獲批品種,為《國家醫保目錄》常規目錄品種;逍遙片退出《國家醫保目錄》。除上述調整的產品外,公司其他納入《國家醫保目錄》(2024年)的品種與《國家醫保目錄》(2023年)保持不變。目前,公司共有114個品種納入《國家醫保目錄》,其中甲類48個,乙類66個。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.